A. Davila

Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.

Aaron R Cooper, M. Pellegrini, D. Kohn, 2017, Blood.

Long-term Outcomes after Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (ADA SCID).

Aaron M. Rosenfeld, F. Bushman, K. Cornetta, 2021, Blood.

Evaluation of clonal hematopoiesis in pediatric ADA-SCID gene therapy participants

D. Kohn, Vivian Y. Chang, J. Carroll, 2022, Blood advances.

Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency.

K. Cornetta, M. Hershfield, G. Crooks, 2021, The New England journal of medicine.

Clinical efficacy of gene-modified stem cells in adenosine deaminase–deficient immunodeficiency

Barbara Engel, John Tse, David Gjertson, 2017, The Journal of clinical investigation.

Apheresis of Deceased Donors as a New Source of Mobilized Peripheral Blood Hematopoietic Stem Cells for Transplant Tolerance

B. Naini, E. Reed, J. Veale, 2022, Transplantation.